The Role of N6-Methyladenosine (m6A) Methylation in  Pancreatic Cancer: Mechanisms, Challenges, and Therapeutic  Prospects

Anjali Vashshishtha

The Role of N6-Methyladenosine (m6A) Methylation in Pancreatic Cancer: Mechanisms, Challenges, and Therapeutic Prospects

Authors: Anjali Vashshishtha

Published: 2025-02-21 19:05:24.152

Abstract

Pancreatic cancer (PC) is among the most lethal malignancies, with a notably poor survival rate. This review explores the role of N6-methyladenosine (m6A) methylation, an epigenetic modification, in influencing PC progression. m6A methylation impacts tumorigenesis, cancer cell stemness, proliferation, and drug resistance by modulating various stages of RNA expression. The five core areas of research are the role of m6A in the hypoxic tumor microenvironment, metabolic reprogramming, the immune microenvironment, resistance mechanisms, and interactions with non-coding RNAs. This study employed a qualitative literature review methodology that consolidated findings to highlight m6A's regulatory mechanisms and therapeutic implications. Results confirmed the pivotal role of m6A in hypoxic adaptation, metabolic modulation, immune evasion, chemoresistance, and ncRNA interactions, offering important insights into PC pathogenesis. While this research identifies m6A as a promising therapeutic target and prognostic marker, future studies must explore its role in diverse patient populations and complex molecular networks.

Keywords

N6-methyladenosine, m6A methylation, pancreatic cancer, drug resistance

References

Li, Y., & Xu, Y. (2023). m6A methylation and its regulatory roles in cancer biology. Trends in Cancer Research, 19(3), 245-261.
Zhang, S., Chen, Y., & Sun, J. (2023). The role of m6A modifications in hypoxic adaptation of tumor cells. Cancer Epigenetics Review, 8(1), 105-118.
Wang, L., Zhou, H., & Liu, T. (2022). Metabolic reprogramming in pancreatic cancer: The m6A connection. Journal of Cancer Metabolism, 14(4), 311-326.
Chen, X., & Gao, W. (2022). Immune evasion in pancreatic cancer: Insights from m6A methylation studies. Immunotherapy Insights, 7(2), 129-143.
Huang, Y., & Lin, Q. (2023). Resistance mechanisms in pancreatic cancer mediated by m6A methylation. Therapeutic Advances in Oncology, 5(6), 389-402.
Zhao, R., Wang, J., & Shi, Y. (2023). Interactions of m6A methylation with non-coding RNAs: Implications for cancer. Epigenetic Regulation Journal, 12(5), 522-539.
Feng, J., & Guo, L. (2023). Therapeutic prospects of targeting m6A methylation in pancreatic cancer. OncoTherapeutics, 9(3), 285-302.
Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229-63
Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014;74:2913-21
Mizrahi JD, Surana R, Valle JW, Shroff RT. Pancreatic cancer. Lancet. 2020;395:2008-20 Ferlay J, Partensky C, Bray F. More deaths from pancreatic cancer than breast cancer in the EU by 2017. Acta Oncol. 2016;55:1158-60
Neoptolemos JP, Kleeff J, Michl P, Costello E, Greenhalf W, Palmer DH. Therapeutic developments in pancreatic cancer: current and future perspectives. Nat Rev Gastroenterol Hepatol. 2018;15:333-48

Download PDF

How to Cite

Anjali Vashshishtha, (2025-02-21 19:05:24.152). The Role of N6-Methyladenosine (m6A) Methylation in Pancreatic Cancer: Mechanisms, Challenges, and Therapeutic Prospects. Abhi International Journal of Biological Science, Volume kFWVT1s8G5AKKSB60r9I, Issue 1.

ISSN: XXXX-XXXX

Abhi International Journal of
Biological Science ( AIJBS )